PHPaméla Houée

Paméla Houée

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paméla Houée has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Agnès Perrin-Guyomard

    ANSES-Fougères Laboratory (French National Agency for Food, Environment and Occupational Health & Safety), 10 B, rue Claude Bourgelat - Javené, CS 40608, 35306 CEDEX Fougères, France

    1 shared publication
  • Arnaud Bridier

    Antibiotics, Biocides, Residues and Resistance unit, French Agency for Food, Environmental and Occupational Health & Safety (Anses), Fougères Laboratory, Bâtiment Bioagropolis, Javené, France

    1 shared publication
  • Christophe Soumet

    ANSES, Unit of Antibiotics, Biocides, Residues, and Resistance (AB2R), F-35306 Fougères, France

    1 shared publication
  • Clémence Cuzin

    Antibiotics, Biocides, Residues and Resistance Unit, Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 35300 Fougères, France

    1 shared publication
  • Jacqueline Manceau

    ANSES, Fougères Laboratory, Scientific Support Unit, 10B rue Claude Bourgelat, Javené, CS 40608, Fougères 35306, France

    1 shared publication
  • Jean-Guy Rolland

    ANSES, Fougères Laboratory, Scientific Support Unit, 10B rue Claude Bourgelat, Javené, CS 40608, Fougères 35306, France

    1 shared publication

Latest Publications

  • Open Access

    Selection of a Gentamicin-Resistant Variant Following Polyhexamethylene Biguanide (PHMB) Exposure in Escherichia coli Biofilms

    by Clémence Cuzin, Paméla Houée, Pierrick Lucas, Yannick Blanchard, Christophe Soumet, Arnaud Bridier

    Antibiotic resistance is one of the most important issues facing modern medicine. Some biocides have demonstrated the potential of selecting resistance to antibiotics in bacteria, but data are still very scarce and it is important to better identify the molecules concerned and the underlying mechanisms. This study aimed to assess the potential of polyhexamethylene biguanide (PHMB), a widely used biocide in a variety of sectors, to select antibiotic resistance in Escherichia coli grown in biofilms. Biofilms were grown on inox coupons and then exposed daily to sublethal concentrations of PHMB over 10 days. Antibiotic-resistant variants were then isolated and characterized phenotypically and genotypically to identify the mechanisms of resistance. Repeated exposure to PHMB led to the selection of an E. coli variant (Ec04m1) with stable resistance to gentamycin (8-fold increase in minimum inhibitory concentration (MIC) compared to the parental strain. This was also associated with a significant decrease in the growth rate in the variant. Sequencing and comparison of the parental strain and Ec04m1 whole genomes revealed a nonsense mutation in the aceE gene in the variant. This gene encodes the pyruvate dehydrogenase E1 component of the pyruvate dehydrogenase (PDH) complex, which catalyzes the conversion of pyruvate to acetyl-CoA and CO2. A growth experiment in the presence of acetate confirmed the role of this mutation in a decreased susceptibility to both PHMB and gentamicin (GEN) in the variant. This work highlights the potential of PHMB to select resistance to antibiotics in bacteria, and that enzymes of central metabolic pathways should be considered as a potential target in adaptation strategies, leading to cross-resistance toward biocides and antibiotics in bacteria.


  • Open Access

    Risk Assessment of Deoxynivalenol by Revisiting Its Bioavailability in Pig and Rat Models to Establish Which Is More Suitable

    by Manuel Jimmy Saint-Cyr, Agnès Perrin-Guyomard, Jacqueline Manceau, Paméla Houée, Jean-Michel Delmas, Jean-Guy Rolland, Michel Laurentie

    Due to its toxic properties, high stability, and prevalence, the presence of deoxynivalenol (DON) in the food chain is a major threat to food safety and therefore a health risk for both humans and animals. In this study, experiments were carried out with sows and female rats to examine the kinetics of DON after intravenous and oral administration at 100 µg/kg of body weight. After intravenous administration of DON in pigs, a two-compartment model with rapid initial distribution (0.030 ± 0.019 h) followed by a slower terminal elimination phase (1.53 ± 0.54 h) was fitted to the concentration profile of DON in pig plasma. In rats, a short elimination half-life (0.46 h) and a clearance of 2.59 L/h/kg were estimated by sparse sampling non-compartmental analysis. Following oral exposure, DON was rapidly absorbed and reached maximal plasma concentrations (Cmax) of 42.07 ± 8.48 and 10.44 ± 5.87 µg/L plasma after (tmax) 1.44 ± 0.52 and 0.17 h in pigs and rats, respectively. The mean bioavailability of DON was 70.5% ± 25.6% for pigs and 47.3% for rats. In the framework of DON risk assessment, these two animal models could be useful in an exposure scenario in two different ways because of their different bioavailability.